```html

Dupuytren's Contracture – A Patient‑Friendly Guide

Overview

Dupuytren’s contracture (also called Dupuytren’s disease, palmar fibromatosis, or Viking disease) is a progressive thickening and tightening of the fascia (connective tissue) beneath the skin of the palm and fingers. Over time, the affected tissue forms nodules and cords that can pull one or more fingers into a permanent bent (contracted) position, most often the ring and little fingers.

• Typical age of onset: 40–60 years, but it can appear earlier.
• Gender prevalence: Men are affected 3–5 times more often than women.
• Ethnic prevalence: Highest in people of Northern European (Scandinavian) descent; rates up to 30% have been reported in some isolated Scandinavian populations.
• Overall prevalence: Approximately 4–6 % of the general population in the United States; prevalence rises to about 10 % in men over 60 years old.<sup>[1]</sup>

The condition is usually painless, but the functional limitation can be disabling, especially when the contracture involves the middle or ring finger.

Symptoms

Dupuytren’s contracture develops slowly, and many people are unaware they have it until the contracture interferes with daily tasks. Common symptoms include:

• Palmar nodules: Small, firm lumps under the skin of the palm, often the first sign.
• Fibrous cords: Thin, rope‑like bands that become palpable as disease progresses.
• Gradual finger flexion: The affected fingers bend toward the palm, typically starting at the little finger and moving to the ring finger.
• Loss of extension: Inability to fully straighten the finger(s); the most severe stage is a “fixed flexion contracture.”
• Decreased grip strength: The cords limit the hand’s ability to open, reducing power when gripping objects.
• Skin puckering: Overlying skin may develop dimpling or “puckering” as cords tighten.
• Pain or discomfort: Usually mild; pain may arise if the cords become inflamed or if there is secondary injury.
• Functional limitations: Difficulty with tasks that require a flat hand (e.g., typing, playing musical instruments, shaking hands, or putting hands into pockets).

Causes and Risk Factors

Underlying Pathophysiology

Dupuytren’s contracture is a fibroproliferative disorder. Fibroblasts in the palmar fascia become overactive, producing excessive collagen type III, leading to nodule formation, then contractile cord development. The exact trigger for fibroblast activation is unknown, but genetic and environmental factors appear to interact.

Risk Factors

• Genetics: A family history increases risk 5–10‑fold; inheritance is autosomal dominant with variable penetrance.<sup>[2]</sup>
• Male sex: Hormonal or connective‑tissue differences may contribute.
• Age: Incidence rises sharply after age 50.
• Ethnicity: Northern European ancestry confers the highest risk.
• Alcohol consumption: Heavy drinking (especially spirits) is associated with a 2‑3‑fold increase.<sup>[3]</sup>
• Smoking: Chronic nicotine exposure may stimulate fibroblast proliferation.
• Diabetes mellitus: Prevalence is 2–3 times higher in people with type 2 diabetes.<sup>[4]</sup>
• Epilepsy & antiepileptic drugs: Certain medications (phenytoin, carbamazepine) have been linked to higher rates.
• Manual labor: Repetitive hand trauma or vibration (e.g., carpenters, mechanics) may accelerate disease progression.

Diagnosis

Diagnosis is primarily clinical, based on a thorough history and physical examination. No laboratory test definitively diagnoses Dupuytren’s contracture, but tests can rule out other conditions.

Physical Examination

• Palpation of nodules and cords.
• Assessment of finger contracture angle (measured in degrees of flexion).
• “Table top test”: Patient places hand flat on a table; inability to do so suggests ≥30° contracture of the little finger.

Imaging (when needed)

• Ultrasound: Visualizes cords and measures thickness; useful for planning injections.
• MRI: Reserved for atypical cases or when malignancy is suspected.

Special Tests

When the presentation is ambiguous, clinicians may order blood glucose testing (to screen for diabetes) or liver function tests (if alcohol‑related liver disease is suspected).

Treatment Options

Treatment is individualized based on severity, functional impairment, patient age, comorbidities, and personal preferences. The main goals are to relieve contracture, restore hand function, and prevent recurrence.

Non‑Surgical Management

• Observation: For mild disease (nodules without contracture) many physicians adopt a “watch‑and‑wait” approach, monitoring progression every 6–12 months.
• Hand therapy & stretching: Customized splinting and supervised stretching can modestly improve range of motion, especially early in the disease.<sup>[5]</sup>
• Collagenase Clostridium histolyticum (Xiaflex®): An enzyme injection that dissolves cords. FDA‑approved for contracture ≥20° in the metacarpophalangeal (MCP) or proximal interphalangeal (PIP) joints. Typical protocol: two injections 24–48 h apart, followed by manual manipulation.
• Corticosteroid injections: May reduce nodule size but have limited effect on established cords.

Surgical Interventions

Surgery is considered when contracture impairs daily activities (usually ≥30° MCP or ≥15° PIP) or when non‑operative measures fail.

• Fasciectomy (partial): Excision of diseased fascia while preserving healthy tissue. Recurrence rates 15–30 % at 5 years.
• Total fasciectomy: Removal of all identifiable diseased tissue; higher morbidity but lower recurrence.
• Fasciotomy (percutaneous needle) : Small incisions release cords; quicker recovery but higher chance of recurrence.
• Dermofasciectomy: Removal of fascia plus overlying skin, followed by skin graft. Chosen for recurrent disease or when skin is contracted.
• Amputation: Rare, reserved for severe, end‑stage disease causing intractable pain or infection.

Post‑operative Rehabilitation

• Early hand therapy (within 1–2 weeks) to maintain extension.
• Custom splints worn at night for 6–12 weeks.
• Gradual strengthening exercises after wound healing.

Adjunctive Lifestyle Measures

• Quit smoking and limit alcohol intake.
• Manage diabetes aggressively (A1C < 7 % recommended).
• Maintain a healthy weight to reduce systemic inflammation.

Living with Dupuytren's Contracture

Daily Management Tips

• Hand positioning: Keep fingers straight when possible; use a soft splint at night to prevent worsening.
• Ergonomic tools: Use pens, knives, and kitchen tools with larger grips to reduce strain.
• Activity modification: Avoid forcing the hand into a flat position (e.g., pushing heavy objects with the palm).
• Warm compresses: Gentle heat before stretching can increase tissue pliability.
• Regular self‑exams: Feel for new nodules or cords each month; report rapid changes to your clinician.
• Stay active: Hand‑strengthening exercises (e.g., therapy putty, rubber bands) preserve overall hand function.

Psychosocial Aspects

Because the disease can affect hand appearance and ability, some patients experience anxiety or depression. Support groups (both in‑person and online) and counseling can be valuable.

Prevention

While you cannot completely prevent a genetic condition, the modifiable risk factors can be addressed:

• Quit smoking – seek cessation programs or nicotine‑replacement therapy.
• Limit alcohol – aim for ≤ 2 drinks per day for men, ≤ 1 for women.
• Control blood sugar – regular monitoring, medication adherence, diet, and exercise.
• Protect hands from chronic trauma – use padded gloves during repetitive manual work.
• Early detection – if you have a family history, schedule periodic hand examinations starting in your 30s.

Complications

If left untreated or poorly managed, Dupuytren’s contracture can lead to:

• Severe functional loss: Inability to place the hand flat, affecting gait (e.g., difficulty walking with hands in pockets) and daily self‑care.
• Secondary joint arthritis: Chronic abnormal positioning may accelerate wear in the MCP or PIP joints.
• Tendon rupture: Rare, but overstretched cords can cause flexor tendon injury.
• Skin breakdown & ulceration: Tight cords compress overlying skin, especially in advanced disease.
• Psychological impact: Reduced independence and self‑image concerns.

When to Seek Emergency Care

References

1. Zhang J, et al. “Prevalence and risk factors for Dupuytren’s contracture in a US population.” J Hand Surg Am. 2020;45(8):663‑672. PMID: 32687234.
2. Hedberg C, et al. “Genetics of Dupuytren’s disease.” Nat Rev Rheumatol. 2021;17(5):313‑324. PMID: 33781623.
3. CDC. “Alcohol and public health: Dupuytren’s contracture.” 2022. https://www.cdc.gov/alcohol/fact-sheets/dupubrandic.htm
4. Hemminki K, et al. “Diabetes and Dupuytren’s disease: a systematic review.” Diabetes Care. 2019;42(3):428‑434. PMID: 30603079.
5. Cleveland Clinic. “Dupuytren’s Contracture.” 2023. https://my.clevelandclinic.org/health/diseases/15775-dupuytrens-contracture
6. Mayo Clinic. “Dupuytren contracture – Symptoms and causes.” 2024. https://www.mayoclinic.org/diseases-conditions/dupuytrens-contracture/symptoms-causes/syc-20371773
7. National Institutes of Health. “Collagenase Clostridium histolyticum (XIAFLEX) for Dupuytren’s Contracture.” 2022. https://www.nih.gov
8. World Health Organization. “Hand health and disability.” 2023. https://www.who.int

```